Ginette Serrero received a PhD in Biochemistry from the University of Marseille and a D.Sc. in Cell Biology from the University of Nice in France. She carried out post-doctoral studies in Cancer Biology at the University of California San Diego in the laboratory of Dr. Gordon Sato. She was a Senior Scientists at he W. Alton Jones Cell Science in Lake Placid, NY with adjunct faculty appointments at Clarkson College in Postdam NY and at the University of Vermont. She then moved to The University of Maryland in Baltimore in the Department of Pharmaceutical Sciences at the School of Pharmacy and the Program in Oncology of the University of Maryland Cancer Center first as an Associate and then Full Professor. She founded the biotech company A&G Pharmaceutical Inc, located in Columbia, MD, a company developing theranostic diagnostic and therapeutic products for breast and lung Cancer and then became its CEO in 2004. She maintains an Adjunct Professor appointment at the University of Maryland Baltimore and at the Greenebaum Comprehensive Cancer Center.
My research activities and professional accomplishments combine basic research with target discovery in oncology as well as translational and IRB approved biomarker clinical studies. Together with my previous and current academic positions, my role as CEO of A&G Pharmaceutical Inc, a company I founded, enables me to bring a combination of academic and industry biotech experience to the development of new oncology products.
The focus of A&G Pharmaceutical is to identify theranostic targets that have both diagnostic and therapeutic targets as solutions to personalized medicine in Oncology and develop diagnostic and therapeutic products based on the identified targets. Prior to founding A&G, I was a Professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy and Program of Oncology at the University of Maryland Greenebaum Cancer Center (UMGCC). I am presently an Adjunct Professor in Pharmaceutical Sciences and Pathology at the University of Maryland and member of the UMGCCC.
For several years I have been involved in the discovery of novel targets associated with differentiation and with increased tumorigenicity of cancer cells. My approach has been to focus on theranostic (target that have both diagnostic and therapeutic applications) based on applying a biological screen to target mining. My laboratory was the first one to clone a major lipid droplet component named ADRP, one of the members of the perilipin family upregulated during adipose differentiation. Subsequently, my laboratory was the first to purify the 88kDa GP88 or progranulin from the conditioned medium of highly tumorigenic cells and show its role in the proliferation and survival of cancer cells. I have several US and international patents cxovering this biomarker for use in disease diagnostics and therapy.
I have developed two diagnostic kits for measurement of GP88 in serum and tumor biopsies manufactured under GMP conditions. The tissue test Oncostain88TM is currently awaiting FDA approval for assessing risk of recurrence in ER+ Invasive Breast Cancer. Additionally I have developed a therapeutic monoclonal anti-GP88 for use in cancer. This antibody is currently undergoing toxicology prior to entering human studies.
Since its discovery, I have become a leading scientist on the study of GP88/progranulin and am experienced in protein biochemistry, cellular biology and molecular biology. Throughout this discovery and development process I have developed productive collaborations with several institutions, clinicians and academic scientists and I have been involved in directing multi team projects; I have authored 83 peer-reviewed publications, several reviews and book chapters. Throughout my career, I have received several grants including American Heart Association, Juvenile Diabetes Foundation, Susan G. Komen Foundation, DOD and NIH RO1, SBIR Phase I and Phase II and Avon Foundation.
Lab Techniques and Equipment:
Expertise in mammalian cell culture including large scale , mouse xenografts, protein purification and characterization, molecular cloning, antibody development, hybridoma development, biomarker identification and translational studies, IHC, ELISA.